Organisation paid for research Program year 2025 Source: CMS Open Payments

San Juan Med

Neither a doctor nor a teaching hospital

Research payments

$2,033,763

517 payments

Through program year 2025, San Juan Med is reported as receiving $2,033,763 in research payments, across 517 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$10,297	5
2021	Research	$877,718	267
2020	Research	$1,145,748	245

Breakdown

Who paid Research payments · program years 2020–2025

AbbVie, Inc. $2,033,763 517 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $354,000 21 payments
M19-130 $271,539 16 payments
M15-998 $217,212 19 payments
M15-554 $201,803 30 payments
M16-047 $147,477 39 payments
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) $88,696 34 payments
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $84,768 36 payments
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) $79,585 19 payments
A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT) $57,288 16 payments
M16-560 $52,662 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.